Patents by Inventor Daniel O'Malley
Daniel O'Malley has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 12391675Abstract: The present invention provides compounds of Formula (I): (I) wherein all of the variables are as defined herein. These compounds are modulators of NLRP3, which may be used as medicaments for the treatment of proliferative disorders, such as cancer in a subject (e.g., a human).Type: GrantFiled: January 13, 2020Date of Patent: August 19, 2025Assignee: Innate Tumor Immunity, Inc.Inventors: Ashvinikumar V. Gavai, Derek J. Norris, Daniel O'Malley, Steven P. Seitz, Jay A. Markwalder, David K. Williams, Hua Gong, Scott Hunter Watterson, Christine M. Tarby
-
Publication number: 20250221966Abstract: The disclosure relates to compounds of Formula (I), which are RXFP1 receptor agonists, compositions containing them, and methods of using them, for example, in the treatment of heart failure, fibrotic diseases, and related diseases such as lung disease (e.g., idiopathic pulmonary fibrosis), kidney disease (e.g., chronic kidney disease), or hepatic disease (e.g., non-alcoholic steatohepatitis and portal hypertension).Type: ApplicationFiled: October 28, 2022Publication date: July 10, 2025Inventors: Shun Su, Donna M. Bilder, Adam James Clarke, Heather Finlay, Todd J. Friends, Arvind Mathur, Michael C. Myers, R. Michael Lawrence, Jianqing Li, Donald J.P. Pinto, Michael J. Orwat, Kumar Balashanmuga Pabbisetty, Scott A. Shaw, Leon M. Smith, II, George O. Tora, Benjamin P. Vokits, Daniel O'Malley, Nicholas R. Wurtz, Vikram Bhogadi, Laxman Pasunoori, Pitani Veera Venkata Srinivas, Sreekantha Ratna Kumar, Hima Kiran Potturi, Subramanya Hegde
-
Patent number: 12351580Abstract: This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that modulate (e.g., agonizes or partially agonizes) NLRP3 that are useful, e.g., for treating a condition, disease or disorder in which an increase in NLRP3 signaling may correct a deficiency in innate immune activity (e.g., a condition, disease or disorder associated with an insufficient immune response) that contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also features compositions as well as other methods of using and making the same.Type: GrantFiled: October 17, 2023Date of Patent: July 8, 2025Assignee: Innate Tumor Immunity, Inc.Inventors: Gary D. Glick, Shomir Ghosh, William R. Roush, Edward James Olhava, Daniel O'Malley
-
Patent number: 12338228Abstract: The present invention provides compounds of Formula (I), (II) or (III): (I), (II), (III), wherein all of the variables are as defined herein. These compounds are modulators of NLRP3, which may be used as medicaments for the treatment of proliferative disorders, such as cancer in a subject (e.g., a human).Type: GrantFiled: January 13, 2020Date of Patent: June 24, 2025Assignee: Innate Tumor Immunity, Inc.Inventors: Scott Hunter Watterson, Daniel O'Malley, Ashvinikumar V. Gavai, Patrice Gill, Steven P. Seitz, Hua Gong
-
Patent number: 12333237Abstract: Systems, methods, and non-transitory computer readable media may provide a view of geospatial information. A user's selection of a location may be obtained. Characteristic information describing characteristics of the location may be obtained. Activities information describing activities of the location may be obtained. An interface (e.g., user interface, API) enabling presentation of a geospatial view of the activities of the location with respect to the characteristics of the location may be provided.Type: GrantFiled: March 6, 2023Date of Patent: June 17, 2025Assignee: Palantir Technologies Inc.Inventors: Alexander Mark, Andrew Elder, Brandon Marc-Aurele, David Montague, Eric Knudson, Eric Jeney, Jeffrey Bagdis, Daniel O'Malley, Vincent Tilson
-
Patent number: 12187706Abstract: The present invention provides compounds of Formula (I): Formula (I) wherein all of the variables are as defined herein. These compounds are modulators of NLRP3, which may be used as medicaments for the treatment of proliferative disorders, such as cancer in a subject (e.g., a human).Type: GrantFiled: January 13, 2020Date of Patent: January 7, 2025Assignee: Innate Tumor Immunity, Inc.Inventors: Daniel O'Malley, Ashvinikumar V. Gavai, Derek J. Norris, Hua Gong, Yong Zhang, Patrice Gill, Christine M. Tarby, Matthias Broekema, Scott Hunter Watterson
-
Patent number: 12171756Abstract: The present invention provides compounds of Formula (I): wherein all of the variables are as defined herein. These compounds are modulators of NLRP3, which may be used as medicaments for the treatment of proliferative disorders, such as cancer in a subject (e.g., a human).Type: GrantFiled: April 28, 2022Date of Patent: December 24, 2024Assignee: INNATE TUMOR IMMUNITY, INC.Inventors: Daniel O'Malley, Ashvinikumar V. Gavai, Patrice Gill, Christine M. Tarby, Scott Hunter Watterson, Hua Gong, David K. Williams, Shomir Ghosh, William R. Roush
-
Patent number: 12150937Abstract: The present invention provides compounds of Formula (I): wherein all of the variables are as defined herein. These compounds are modulators of NLRP3, which may be used as medicaments for the treatment of proliferative disorders, such as cancer in a subject (e.g., a human).Type: GrantFiled: January 20, 2020Date of Patent: November 26, 2024Assignee: Innate Tumor Immunity, Inc.Inventors: Scott Hunter Watterson, Daniel O'Malley, Ashvinikumar V. Gavai, Hua Gong, Christine M. Tarby
-
Publication number: 20240067649Abstract: This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that modulate (e.g., agonizes or partially agonizes) NLRP3 that are useful, e.g., for treating a condition, disease or disorder in which an increase in NLRP3 signaling may correct a deficiency in innate immune activity (e.g., a condition, disease or disorder associated with an insufficient immune response) that contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also features compositions as well as other methods of using and making the same.Type: ApplicationFiled: October 17, 2023Publication date: February 29, 2024Inventors: Gary D. Glick, Shomir Ghosh, William R. Roush, Edward James Olhava, Daniel O'Malley
-
Patent number: 11827632Abstract: This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that modulate (e.g., agonizes or partially agonizes) NLRP3 that are useful, e.g., for treating a condition, disease or disorder in which an increase in NLRP3 signaling may correct a deficiency in innate immune activity (e.g., a condition, disease or disorder associated with an insufficient immune response) that contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also features compositions as well as other methods of using and making the same.Type: GrantFiled: May 6, 2021Date of Patent: November 28, 2023Assignee: INNATE TUMOR IMMUNITY, INCInventors: Gary D. Glick, Shomir Ghosh, William R. Roush, Edward James Olhava, Daniel O'Malley
-
Patent number: 11803532Abstract: Systems and methods are provided for integrated data analysis. At least one object that is responsive to a first search query is determined. The object is stored in an object model that is managed by a first computing platform, and the at least one object is associated with one or more properties. One or more data sets that are responsive to a second search query are determined. The data sets are managed by a second computing platform. The one or more data sets are determined related to the at least one object. The at least one object is updated to include at least one property that references at least one analysis that relies on the one or more data sets.Type: GrantFiled: August 5, 2021Date of Patent: October 31, 2023Assignee: Palantir Technologies Inc.Inventors: Alexander Mark, Andrew Elder, Caitlin Colgrove, Daniel O'Malley, Hannah Korus, Michael Barone, Sharon Hao, William Rhyne
-
Publication number: 20230293303Abstract: According to an aspect, an electronic pump assembly includes a pump configured to move fluid between from or to a fluid reservoir of a device. The pump includes a passive valve. The electronic pump assembly includes a controller configured to actuate the pump and a flow modifier configured to restrict a flow of fluid entering or within the pump.Type: ApplicationFiled: March 14, 2023Publication date: September 21, 2023Inventors: Daragh Nolan, Barbara Belisa Soffiati, Thomas Sinnott, Evania Ann Mareena, Shauna O'Meara, Eduardo Marcos Larangeira, Noel Smith, Daniel O'Malley
-
Publication number: 20230205977Abstract: Systems, methods, and non-transitory computer readable media may provide a view of geospatial information. A user's selection of a location may be obtained. Characteristic information describing characteristics of the location may be obtained. Activities information describing activities of the location may be obtained. An interface (e.g., user interface, API) enabling presentation of a geospatial view of the activities of the location with respect to the characteristics of the location may be provided.Type: ApplicationFiled: March 6, 2023Publication date: June 29, 2023Inventors: Alexander MARK, Andrew ELDER, Brandon MARC-AURELE, David MONTAGUE, Eric KNUDSON, Eric JENEY, Jeffrey BAGDIS, Daniel O'MALLEY, Vincent TILSON
-
Publication number: 20230140430Abstract: Compounds according to formula I are useful as agonists of Toll-like receptor 7 (TLR7). Such compounds can be used in cancer treatment, especially in combination with an anti-cancer immunotherapy agent, or as a vaccine adjuvant.Type: ApplicationFiled: January 26, 2021Publication date: May 4, 2023Inventors: Matthew COX, Liqi HE, Sanjeev GANGWAR, Ashvinikumar V. GAVAI, Matthias BROEKEMA, Qiang CONG, Daniel O'MALLEY, Yam B. POUDEL, Christine M. TARBY
-
Publication number: 20230122249Abstract: Compounds according to formula I are useful as agonists of Toll-like receptor 7 (TLR7). (I) Such compounds can be used in cancer treatment, especially in combination with an anti-cancer immunotherapy agent, or as a vaccine adjuvant.Type: ApplicationFiled: January 26, 2021Publication date: April 20, 2023Applicant: BRISTOL-MYERS SQUIBB COMPANYInventors: Yam B. POUDEL, Matthew COX, Liqi HE, Daniel O'MALLEY, Ashvinikumar V. GAVAI, Sanjeev GANGWAR, Matthias BROEKEMA, Prasanna SIVAPRAKASAM, Christine M. TARBY, Murugaiah ANDAPPAN MURUGAIAH SUBBAIAH,Murugaiah
-
Patent number: 11599706Abstract: Systems, methods, and non-transitory computer readable media may provide a view of geospatial information. A user's selection of a location may be obtained. Characteristic information describing characteristics of the location may be obtained. Activities information describing activities of the location may be obtained. An interface (e.g., user interface, API) enabling presentation of a geospatial view of the activities of the location with respect to the characteristics of the location may be provided.Type: GrantFiled: May 3, 2018Date of Patent: March 7, 2023Assignee: Palantir Technologies Inc.Inventors: Alexander Mark, Andrew Elder, Brandon Marc-Aurele, David Montague, Eric Knudson, Eric Jeney, Jeffrey Bagdis, Daniel O'Malley, Vincent Tilson
-
Publication number: 20220306630Abstract: The present invention is directed to compounds of the formula (I) wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.Type: ApplicationFiled: August 5, 2020Publication date: September 29, 2022Inventors: Lalgudi S. Harikrishnan, Peter Kinam Park, Zheming Ruan, Donna D. Wei, Daniel O'Malley, Honghe Wan, Ashok Vinayak Purandare, Brian E. Fink
-
Publication number: 20220289736Abstract: This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that modulate (e.g., agonizes or partially agonizes) NLRP3 that are useful, e.g., for treating a condition, disease or disorder in which an increase in NLRP3 signaling may correct a deficiency in innate immune activity (e.g., a condition, disease or disorder associated with an insufficient immune response) that contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also features compositions as well as other methods of using and making the same.Type: ApplicationFiled: May 6, 2021Publication date: September 15, 2022Inventors: Gary D. Glick, Shomir Ghosh, William R. Roush, Edward James Olhava, Daniel O'Malley
-
Publication number: 20220257587Abstract: The present invention provides compounds of Formula (I): wherein all of the variables are as defined herein. These compounds are modulators of NLRP3, which may be used as medicaments for the treatment of proliferative disorders, such as cancer in a subject (e.g., a human).Type: ApplicationFiled: April 28, 2022Publication date: August 18, 2022Inventors: Daniel O'Malley, Ashvinkumar V. Gavai, Patrice Gill, Christine M. Tarby, Scott Hunter Watterson, Hua Gong, David K. Williams, Shomir Ghosh, William R. Roush
-
Patent number: 11344543Abstract: The present invention provides compounds of Formula (I): (I) wherein all of the variables are as defined herein. These compounds are modulators of NLRP3, which may be used as medicaments for the treatment of proliferative disorders, such as cancer in a subject (e.g., a human).Type: GrantFiled: July 12, 2018Date of Patent: May 31, 2022Assignee: Innate Tumor Immunity, Inc.Inventors: Daniel O'Malley, Ashvinikumar V. Gavai, Patrice Gill, Christine M. Tarby, Scott Hunter Watterson, Hua Gong, David K. Williams, Shomir Ghosh, William R. Roush